PURPOSE: SARS-CoV-2 (COVID-19) is a systemic infection. Patients with cancer are immunocompromised and may be vulnerable to COVID-related morbidity and mortality. The objectives of this study were to determine if patients with cancer have worse outcomes compared with patients without cancer and to identify demographic and clinical predictors of morbidity and mortality among patients with cancer. METHODS: We used data from adult patients who tested positive for COVID-19 and were admitted to two New York-Presbyterian hospitals between March 3 and May 15, 2020. Patients with cancer were matched 1:4 to controls without cancer in terms of age, sex, and number of comorbidities. Using Kaplan-Meier curves and the log-rank test, we compared morbidity (intensive care unit admission and intubation) and mortality outcomes between patients with cancer and controls. Among those with cancer, we identified demographic and clinical predictors of worse outcomes using Cox proportional hazard models. RESULTS: We included 585 patients who were COVID-19 positive, of whom 117 had active malignancy, defined as those receiving cancer-directed therapy or under active surveillance within 6 months of admission. Presenting symptoms and in-hospital complications were similar between the cancer and noncancer groups. Nearly one half of patients with cancer were receiving therapy, and 45% of patients received cytotoxic or immunosuppressive treatment within 90 days of admission. There were no statistically significant differences in morbidity or mortality (P = .894) between patients with and without cancer. CONCLUSION: We observed that patients with COVID-19 and cancer had similar outcomes compared with matched patients without cancer. This finding suggests that a diagnosis of active cancer alone and recent anticancer therapy do not predict worse COVID-19 outcomes and therefore, recommendations to limit cancer-directed therapy must be considered carefully in relation to cancer-specific outcomes and death.
PURPOSE:SARS-CoV-2 (COVID-19) is a systemic infection. Patients with cancer are immunocompromised and may be vulnerable to COVID-related morbidity and mortality. The objectives of this study were to determine if patients with cancer have worse outcomes compared with patients without cancer and to identify demographic and clinical predictors of morbidity and mortality among patients with cancer. METHODS: We used data from adult patients who tested positive for COVID-19 and were admitted to two New York-Presbyterian hospitals between March 3 and May 15, 2020. Patients with cancer were matched 1:4 to controls without cancer in terms of age, sex, and number of comorbidities. Using Kaplan-Meier curves and the log-rank test, we compared morbidity (intensive care unit admission and intubation) and mortality outcomes between patients with cancer and controls. Among those with cancer, we identified demographic and clinical predictors of worse outcomes using Cox proportional hazard models. RESULTS: We included 585 patients who were COVID-19 positive, of whom 117 had active malignancy, defined as those receiving cancer-directed therapy or under active surveillance within 6 months of admission. Presenting symptoms and in-hospital complications were similar between the cancer and noncancer groups. Nearly one half of patients with cancer were receiving therapy, and 45% of patients received cytotoxic or immunosuppressive treatment within 90 days of admission. There were no statistically significant differences in morbidity or mortality (P = .894) between patients with and without cancer. CONCLUSION: We observed that patients with COVID-19 and cancer had similar outcomes compared with matched patients without cancer. This finding suggests that a diagnosis of active cancer alone and recent anticancer therapy do not predict worse COVID-19 outcomes and therefore, recommendations to limit cancer-directed therapy must be considered carefully in relation to cancer-specific outcomes and death.
Authors: Evan T Sholle; Joseph Kabariti; Stephen B Johnson; John P Leonard; Jyotishman Pathak; Vinay I Varughese; Curtis L Cole; Thomas R Campion Journal: AMIA Annu Symp Proc Date: 2018-04-16
Authors: Frank M Schmidt; Julia Weschenfelder; Christian Sander; Juliane Minkwitz; Julia Thormann; Tobias Chittka; Roland Mergl; Kenneth C Kirkby; Mathias Faßhauer; Michael Stumvoll; Lesca M Holdt; Daniel Teupser; Ulrich Hegerl; Hubertus Himmerich Journal: PLoS One Date: 2015-03-17 Impact factor: 3.240
Authors: L Zhang; F Zhu; L Xie; C Wang; J Wang; R Chen; P Jia; H Q Guan; L Peng; Y Chen; P Peng; P Zhang; Q Chu; Q Shen; Y Wang; S Y Xu; J P Zhao; M Zhou Journal: Ann Oncol Date: 2020-03-26 Impact factor: 32.976
Authors: Jia Luo; Hira Rizvi; Jacklynn V Egger; Isabel R Preeshagul; Jedd D Wolchok; Matthew D Hellmann Journal: Cancer Discov Date: 2020-05-12 Impact factor: 38.272
Authors: Markus Joerger; Yannis Metaxas; Khalil Zaman; Olivier Michielin; Nicolas Mach; Adrienne Bettini; Andreas M Schmitt; Nathan Cantoni; Clemens B Caspar; Sonja Stettler; Roma Malval; Miklos Pless; Christian Britschgi; Christoph Renner; Dieter Koeberle; Jessica D Schulz; Christoph Kopp; Stefanie Hayoz; Anastasios Stathis; Roger von Moos Journal: Cancers (Basel) Date: 2022-04-27 Impact factor: 6.575
Authors: Samuel M Rubinstein; Divaya Bhutani; Ryan C Lynch; Jeremy L Warner; Michael A Thompson; Chih-Yuan Hsu; Yu Shyr; Shailesh Advani; Ruben A Mesa; Sanjay Mishra; Daniel P Mundt; Dimpy P Shah; R Alejandro Sica; Keith E Stockerl-Goldstein; Catherine Stratton; Matthias Weiss; Alicia Beeghly-Fadiel; Melissa Accordino; Sarit E Assouline; Joy Awosika; Ziad Bakouny; Babar Bashir; Stephanie Berg; Mehmet Asim Bilen; Cecilia A Castellano; Jacob C Cogan; Devendra Kc; Christopher R Friese; Shilpa Gupta; Daniel Hausrath; Clara Hwang; Nathalie A Johnson; Monika Joshi; Anup Kasi; Elizabeth J Klein; Vadim S Koshkin; Nicole M Kuderer; Daniel H Kwon; Chris Labaki; Tahir Latif; Eric Lau; Xuanyi Li; Gary H Lyman; Rana R McKay; Gayathri Nagaraj; Amanda Nizam; Taylor K Nonato; Adam J Olszewski; Hyma V Polimera; Andrew J Portuguese; Matthew M Puc; Pedram Razavi; Rachel Rosovski; Andrew Schmidt; Sumit A Shah; Aditi Shastri; Christopher Su; Pallawi Torka; Trisha M Wise-Draper; Leyre Zubiri Journal: Blood Cancer Discov Date: 2022-05-05
Authors: Antoni Ribas; Rajarshi Sengupta; Trevan Locke; Sayyed Kaleem Zaidi; Katie M Campbell; John M Carethers; Elizabeth M Jaffee; E John Wherry; Jean-Charles Soria; Gypsyamber D'Souza Journal: Cancer Discov Date: 2020-12-19 Impact factor: 38.272